M., Young, R
Metabolic benefits: Gains in lipid profile, blood pressure, and cardiovascular risk markers [1] [5]
In patients with type 2 diabetes mellitus administered sitagliptin 100 mg (N=81) or sitagliptin 200 mg (N=63) daily, there were no meaningful changes in QTc interval based on ECG data obtained at the time of expected peak plasma concentration
The supplement-diet connection Supplements fill gaps
In a study of 80 obese people with type 2 diabetes receiving semaglutide and dulaglutide, a 20% reduction in the thickness of EAT was observed (62) One meta-analysis demonstrated the cardioprotective effects of GLP-1 RAs, showing reductions in blood pressure and lipid profile, with a significant increase in HDL levels (63)
In a 48-week trial of 338 adults with obesity, participants randomized to the 12 mg dose achieved a mean weight loss of 24.2%, which equated to approximately 26.2 kg for a person at a high starting weight